Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia

NCT00538694 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2019-11-14

No results posted yet for this study

Summary

To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.

Conditions

  • Pneumonia, Bacterial

Interventions

DRUG

daptomycin

Sponsors & Collaborators

  • Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-31
Primary Completion
2001-09-30
Completion
2001-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00538694 on ClinicalTrials.gov